Advances in the therapy of rheumatoid arthritis with biological agents

Bibliography

• CHIKANZA IC: The neuroendocrine immunology ofrheumatoid arthritis. Bailliere's Gun. Rheumatol. (1996) 10:273–293.
   PubMed Web of Science ®Google Scholar
• Maddison PS (Ed.), Oxford Medical Publications, Oxford, UK (1993):621–638.
   Google Scholar
• CHIKANZA IC, GROSSMAN AS: Neuroendocrineimmune responses to inflammation: the concept of the neuroendocrine immune loop. Bailliere's Rheumatol. (1996) 10:199–225.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, GREENE JL, TAN P, et al.: Co-expression andfunctional co-operation of CTLA4 and CD28 on activated lymphocytes. J. Exp. Med. (1 9 9 2) 176:1595-1604.
   Google Scholar
• AKIRA S, HIRANO T, TAGA T, KISHIMOTO I: Biology ofmulti-functional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J (1990) 4:2860–2867.
   PubMed Web of Science ®Google Scholar
• CALANDRA T, BUCALA R: Macrophage inhibitoryfactor: a glucocorticoid counter-regulator within the immune system. Grit. Rev. Immunol (1997) 17:77–88.
   PubMed Web of Science ®Google Scholar
• KWON OJ, JUE DM: Pro-tumour necrosis factorcleavage factor enzyme in macrophages membrane particulate. Immunology (1993) 83:134–139.
   Google Scholar
• WILSON KP, BLACK J-AF, THOMSON JA, et al.: Structureand mechanism of action of interleukin-1p converting enzyme. Nature (1994) 3 7 0:270–275.
   Google Scholar
• SECKINGER P, VEY E, TURCATTI G, WINGFIELD P, DAYERJM: TNF inhibitor: purification, NI-I2 terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities. Eur. j Immunol (1990) 20:1167–1174.
   PubMed Web of Science ®Google Scholar
• COLOTTA F, RE F, MUZIO M: Interleukin-1 typereceptor: A decoy target for IL-1 that is regulated by IL-4. Science (1993) 261:472–475.
   PubMed Web of Science ®Google Scholar
• HANAMAIJER R, KOOLWIJK P, LE CLERCQ L: Regulationof metalloproteinase expression in human vein and microvascular endothelial cells. Biochem. J (1993) 296:803–809.
   PubMed Web of Science ®Google Scholar
• MACKAY CR, IMHOF BA: Cell adhesion in the immunesystem. Immunol Today (1993) 14:99–102.
   PubMedGoogle Scholar
• FIRESTEIN GS: Invasive fibroblast-like synoviocytes inrheumatoid arthritis: passive responders or transformed aggressors Arthritis Rheum. (1996) 39:1781–1790.
   Google Scholar
• CHIKANZA IC, ROUX-LOMBARD P, DAYER J-M, PANAYIGS: Dysreg-ulated interleukin-1 receptor antagonist protein production in rheumatoid arthritis; pathoge-netic implications. Arthritis Rheum. (1995) 38:642–648.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN G, BOYLE DL, YU C, et al.: Synovialinterleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. (1994) 37:644–652.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYER JM: Inhibition of the productionand effects of interleukin-1 and tumour necrosis alpha in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151–160.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, CHANTRY D, JACKSON A, et al.: Inhibitory effects of TNF-a antibodies on synovial cell IL-1 production in RA. Lancet ii: 244–247.
   PubMedGoogle Scholar
• PINCUS T: The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin. Arthritis Rheum. (1992) 21 :2–15.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, S JAWED, NAUGHTON D, BLAKE DR: Why do we need new treatments for rheumatoid arthritis Pharm. Pharmacol. (1998) 50:357–369.
   Web of Science ®Google Scholar
• EDWARDS JCW, CAMBRIDGE G, ABRAHAMS VM: Do self perpetuating B lymphocytes drive human autoim-mune disease. Immunology (1999) 97:188–196.
   PubMed Web of Science ®Google Scholar
• ELLIOT MJ, MAINI RN, FELDMAN M, et al.: Treatment of rheumatoid arthritis with chimeric mAb to TNF-a. Arthritis Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• ELLIOT MJ, MAINI RN, FELDMAN M, et al.: Randomiseddouble blind comparison of chimeric antibody to TNF-a (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• KEFFER J, PROBERT L, CAZLARIS H, et al.: Transgenicmice expressing human TNF-a: a predicative genetic model of arthritis. EMBO J. (1991)10:4025-4031.
   Google Scholar
• LORENZ HM, ANTONI L, VALERIS T, et al.: In vivoblockade of TNF-a by IV infusion of chmaeric mAb to TNF-a in patients with RA: short term cellular and molecular effects. J. Immunol. (1996) 156: 1646–1653.
   Google Scholar
• OHSHIMA S, SAEKI Y, MIMA T, et al.: Possiblemechanisms for the long term efficacy of anti-TNF cA2 mAb therapy in RA. Arthritis Rheum. (1996) 39:S242.
   Web of Science ®Google Scholar
• ELLIOT M, MAINI R, FELDMAN M, et al: Repeated therapywith mAb to TNF-a (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1125–1127.
   PubMed Web of Science ®Google Scholar
• CHARLES PJ, ELLIOTT MJ, FELDMANN M, MAINI RN: Development of anti dsDNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF alpha. EULAR J. (1995) 2 4:B114.
   Google Scholar
• PALEOLOG EM, TAYLOR PC, HUNT M, et al: Treatment ofrheumatoid arthritis with antibody to TNF-a decreases expression of and shedding of E-selectin. Arthritis Rheum. (1995) 38:S279.
   Web of Science ®Google Scholar
• MAINI RV, BREEDVELD FC, KALDEN JR, et al.: Therapeuticefficacy of multiple intravenous infusions of anti-tumour necrosis factora monoclonal antibody combined with low-dose weekly methotrexate in Rheumatoid Arthritis. Arthritis Rheum. (19 9 8) 41:1552-1563.
   Google Scholar
• MAINI R, ST CLAIR EW, BREEDVELD F, et al.: Infliximab(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate; a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932–1939.
   PubMed Web of Science ®Google Scholar
• LIPSKY P, ST CLAIR W, FURST D, et al: 54-week clinicaland radiographic results from the ATTRACT trial: a Phase III study of infliximab (Remicade) in patients with active RA despite methotrexate. Arthritis Rheum. (1999) 42 :S401.
   Web of Science ®Google Scholar
• RANKIN ECC, CHOY EHS, EHRENSTEIN MR, et al.:Serological effects of repeated doses of an engineered anti-TNF-a mAb, CDP571 in patients with RA. Arthritis Rheum. (1995) S279.
   Google Scholar
• RANKIN ECC, CHOY EHS, EHRENSTEIN MR, et al.: A double blind, placebo ascending dose trial of the recombinant humanised anti-TNF-a anti-body CDP571 in patients with RA. Arthritis Rheum. (1994) S295.
   Google Scholar
• SCHATTENKIRCHNER M, KRUGER K, SANDER 0 et al.:Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. (1998) 41 :S57 (Abstract).
   Google Scholar
• VAN DE PUTTE LBA, VAN RIEL PLCM, DEN BROEDER A etal.: A single dose placebo controlled Phase I study of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. (1998) 41 :S57.
   Google Scholar
• VAN DE PUTTE LBA, RAU R, BREEDVELD FC, et al.: Efficacy of the fully human anti-TNF antibody D2E7 ion rheumatoid arthritis. Arthritis Rheum. (1999) 42:S400.
   Google Scholar
• RAU R, HERBORN G, SANDER et al.: long-term treatmentwith the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritis Rheum. (1999) 42:S400.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH, et al.:Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH, et al.:Etanercept therapy in rheumatoid arthritis. Arandom-ized, controlled trial. Ann. Intern. Med. (1999) 130: 478–486.
   Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD, et al.: Atrial of etanercept, a recombinant tumor necrosis factor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• FINCK B, MARTIN R, FLEISCHMANN R, MORELAND L, SCHIFF M, BATHON J: A Phase III trial of etanercept vs. methotrexate in early rheumatoid arthritis (Enbrel ERA trial) Arthritis Rheum. (1999) 42:S117.
   Web of Science ®Google Scholar
• LOVELL D, GIANNINI EH, REIFF A, et al: Etanercept inchildren with polyarticular juvenile RA. N Engl. J. Med. (2000) 342:763–769.
   PubMed Web of Science ®Google Scholar
• SANDER O, RAU R, VAN RIEL P, et al: Neutralization ofTNF by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: results of a European Phase II trial. Arthritis Rheum. (1996) 39:S242.
   Web of Science ®Google Scholar
• HASLER F, VAN DE PUTTE L, BAUDIN M et al: Chronic TNF neutralization (up to 1 year) by lenercept (TNFP55-IgG1, Ro 45-2081) in patients with rheuma-toid arthritis: results of an open-label extension of a double-blind single dose Phase I study. Arthritis Rheum. (1996) 3 9 :S243.
   Google Scholar
• EVANS RJ, BENDELE AM, KIEFT GL. et al.: Efficacy of TNF binding protein in streptococcal cell wall arthritis. Arthritis Rheum. (1996) 39:S284.
   Web of Science ®Google Scholar
• MORELAND LW, MCCABE DP, CALDWELL JR, et al: Phase1 /2 trial of methionyl recombinant TNF binding protein PEGylated dimer in patients with refractory RA. J. Rheumatol. (2000) 27:601–609.
   PubMed Web of Science ®Google Scholar
• GEARING AJH, BECKETT P, CHRISTODOULOU M, et al: Processing of tumor necrosis factor alpha precursors by metalloproteinase. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REISFELD DH: Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci. (1990) 11:150–161.
   PubMed Web of Science ®Google Scholar
• SEMMLER JH, WACHTEL H, ENDRES S: The specific Type IV phosphodiesterase inhibitor rolipram suppresses TNF-a production by human mononuclear cells. Int. J. Immunopharmacol. (1993) 15:409–418.
   PubMed Web of Science ®Google Scholar
• SUTTORP N, WEBER U, WELSCH T, SCHUDT C: Role of phosphodiesterase in the regulation of endothelial permeability in vitro. J. Clin. Invest. (1993) 91:1421–1426.
   PubMed Web of Science ®Google Scholar
• SOMMER N, LOSCHMANN PA, NORTHOFF GH, et al.: The anti-depressant rolipram suppresses cytokine production and prevents autoimmune encephalomye-litis. Nature Med. (1995) 1:244–248.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, JAWED S, BLAKE DR, et al.: Treatment of patients with RA with RP-73401 phosphodiesterase Type 4 inhibitor. Arthritis Rheum. (1996) 39:S282.
   Web of Science ®Google Scholar
• LEWTHVVAITE J, BLAKE SM, HARDINGHAM TE, WARDEN PJ, HENDERSON B: The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen-induced arthritis in the rabbit. J. Rheumatol. (1994) 21:467–472.
   PubMed Web of Science ®Google Scholar
• GEIGER T, TOWBIN H, COSENTI-VARGAS A, et al.:Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin. Exp. Rheumatol. (1993) 11: 515–522.
   Google Scholar
• HARDING MW, KU G, FAUST T, LAUFFER LL, LIVING-STONE D: Interleukin-113 converting enzyme inhibi-tion blocks progression of Type 2 collagen induced arthritis in mice. Arthritis Rheum. (1995) S400.
   Google Scholar
• DREVLOW BE, LOVIS R, HAAG MA, et al: Recombinanthuman interleukin-1 receptor Type 1 in the treatment of patients with active RA. Arthritis Rheum. (1996) 39:257–265.
   PubMed Web of Science ®Google Scholar
• BESEDOVSKY H, DEL ROY A, SORKIN E, DINARELLO C: Immunoreg-ulatory feedback between IL-1 and the glucocorticoid hormones. Science (1986) 233:652–666.
   PubMed Web of Science ®Google Scholar
• SVENSON M, HANSEN MB, HEEGARD P, ABELL K, BENDTZEN K: Specific binding of IL-113 and IL-1Ra to human serum: high affinity binding of IL-1Ra to soluble IL-1 receptor Type 1. Cytokine (1993) 5:427–435.
   PubMed Web of Science ®Google Scholar
• SADOUK M, PELLETIER JP, TARDIF K, KIANSA K, CLOUTIER JM, MARTEL-PELLETIER J: Co-expression of IL-1R1 and IL-1R2 in human OA synovial fibroblasts: binding and biological activity is mediated exclusively by Type 1 receptor. Arthritis Rheum. (1994) 37 :S306.
   Google Scholar
• DREVLOW B, CAPEZIO J, LOVIS R, JACOBS C, LANDAY A, POE RM: Phase 1 study of recombinant human interleukin-1 receptor (rHuIL-1R) administered intra-ar ticularly in active rheumatoid arthritis. Arthritis Rheum. (1993) 36:S39.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYER JM: Cytokines and cytokines inhibi-tors or antagonists in rheumatoid arthritis. Arthritis Rheum. (1990) 33:305–315.
   PubMed Web of Science ®Google Scholar
• FISCHER E, VAN ZEE KJ, MORAND MA, et al.: IL-1Ra accumulates in experimental inflammation and human disease. Blood (1992) 79:2192–2200.
   Google Scholar
• LEBSACK ME, PAUL CC, MARTINDALE JJ, CATALANO MA: A dose and regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis (abstract). Arthritis Rheum. (1993) 3 6 :S39.
   Google Scholar
• CAMPION GV, LEBSACK ME, LOOKABAUGH J, GORDON G, CATALANO M: Dose range and dose frequency study of recombinant human IL-1Ra in patients with RA: The IL-1Ra Study Group. Arthritis Rheum. (1 9 9 6) 39:1092-1101.
   Google Scholar
• BRESNIHAN B, ALVARO-GRACIA JM, COBBY M, et al.: Treatment of rheumatoid arthritis with recombinant human in terleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
   PubMed Web of Science ®Google Scholar
• JIANG Y, GENANT HK, WATT I, et al.: A multicentre double blind, dose ranging randomised placebo controlled study of recombinant human IL-1Ra in patients with RA. Arthritis Rheum. (2000) 43:1001–1009.
   PubMed Web of Science ®Google Scholar
• COHEN S, HURD E, CUSH JJ, et al.: Treatment of IL-1Ra in combination with metho trex ate in RA patients. Arthritis Rheum. (1999) 42:S273.
   Google Scholar
• BANDARA G, MUELLER GM, GALEA-LAURI J, et al.: Intra-articular expression of biologically active interleukin-1 receptor antagonist protein by ex-vivo gene transfer. Proc. Natl. Acad. Sci. USA (1993) 9 0 :10764–10768.
   Google Scholar
• ROESSLER FJ, ALLEN ED, WILSON JM, HARTMAN JW, DAVIDSON BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J. Clin. Invest. (1993) 92:1085–1092.
   PubMed Web of Science ®Google Scholar
• HARTMAN JW, DAVIDSON BL, ROESSLER FJ: Genetic modification of synoviocytes in vivo using recombi-nant adenoviral vectors (abstract). Arthritis Rheum. (1993) 36:S64.
   Google Scholar
• WENDLING D, RADACOT E, WIJDENES J: Treatment ofsevere RA by anti-IL-6 mAb. J. Rheumatol. (1993) 20:259–262.
   PubMed Web of Science ®Google Scholar
• ISOMAKI P, LUUKKANES R, SAARIO R, TOIVAREN P, PUNNONEN J: IL-10 functions as an anti-inflammatory cytokine in rheumatoid arthritis. Arthritis Rheum. (1996) 3 9 :386–395.
   Google Scholar
• JOOSTEN LAB, HELSEN MA, VAN DEN BERG WB: Effect ofIL-10on murine SCW arthritis: role of TNF and IL-1 in joint inflammation and cartilage distraction. Arthritis Rheum. (1995) 38:S401.
   Web of Science ®Google Scholar
• KUHLMANN F, ROHLIG C, LUKOSCHEK M, LEMMEL EM,HEILIG B: Effects of IL-10on synovial fluid mononu-clear cells of patients with rheumatic diseases. Arthritis Rheum. (1994) 37:S309.
   Google Scholar
• MAINI RN, PAULUS H, BREEDVELD FC, et al: rHuIL-10 insubjects with rheumatoid arthritis: a Phase I and cytokine response study. Arthritis Rheum. (1997) 40:S224.
   Web of Science ®Google Scholar
• WOODS JM, KATSHKE KJ, TOKUHIRA M, KURATA H, ARAIKI, KOCK AE: Reduction of inflammatory cytokines and PGE2 by IL-13 gene therapy in rheumatoid arthritis synovial cells. Arthritis Rheum. (1999) 42:S94.
   Google Scholar
• GOULD D, CHIKANZA IC, CHERNAJOVSKY Y: Gene therapy targets for RA. Emerging Therapeutic Targets 2000 4(4):481–495.
   Google Scholar
• VAN DEN BOSCH F, RUSSELL A, CHIR B, et al.: rHuIL-4 insubjects with rheumatoid arthritis: a Phase I dose escalating safety study. Arthritis Rheum. (1998) 41:S56
   Google Scholar
• GROUP GLS: Double blind controlled Phase IIImulticenter clinical trial with interferon gamma in rheumatoid arthritis. Rheumatol. Int. (1992) 12: 175–185.
   Google Scholar
• LEMMEL EM, BRACKERTZ D, FRANKE M, et al.: Results of a multicenter placebo-controlled double-blind random-ized Phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol. Int. (1998) 8:87–93.
   Google Scholar
• PERNICE W, SCHUCHMANN L, DIPPELL J, et al.: Therapy for systemic juvenile rheumatoid arthritis treated for one year with interferon-gamma. Z. Rheumatol. (1990) 49:1–7.
   Web of Science ®Google Scholar
• COTO C, VARELA G, HERNANDEZ V, DEL ROSARIO M,LOPEZ-SAURA P: Use of recombinant interferon gamma in pediatric patients with advance juvenile chronic arthritis. Biotherapy (1998) 11: 15–20.
   Google Scholar
• TRIANTAPHYLLOPOULOS KA, WILLIAMS RO, TAILOR et al: Amelioration of collagen induced arthritis and suppression of IFNy, IL-12 and TNE-OC by IFN-I3. Arthritis Rheum. (1999) 42:90–99.
   PubMed Web of Science ®Google Scholar
• TAK PP, HURST BA, KRAAN MC, JONTER M, SMELTS TJM, BREEVELD FC: The effects of IFN-I3 treatment on arthritis. Rheumatology (1999) 38:362–369.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, DAVIS LS, NICHOLS LA, et al.:Treatment of refractory rheumatoid arthritis with monoclonal antibody to ICAM-1. Arthritis Rheum. (1994) 37:992–999.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, RITA J, MCFARLIN J, NICHOLS L, LIPSKY P: Anti-CD54 (ICAM-1) monoclonal antibody therapy in early RA. Arthritis Rheum. (1994) 37:S220.
   Google Scholar
• KAVANAUGH A, DAVIS L, NICHOLS L, LIPSKY P: Re-treatment of RA patients with an anti-ICAM-1 monoclonal antibody. Arthritis Rheum. (1994) 38:S280.
   Web of Science ®Google Scholar
• LINSLEY PS, LEDBETTER JA: The role of CD28 receptor during T cell responses to antigen. Ann. Rev. Immunol (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, WALLACE PM, JOHNSON J, et al.: Irnmuno-suppression in vivo by a soluble form of CTLA-4 T cell activation molecule. Science (1992) 257:792–795.
   PubMed Web of Science ®Google Scholar
• KNOERZER DB, KARR RW, SCHWARTZ BD, MENGLE-GAW LJ: Collagen induced arthritis in the BB rat; prevention of disease by treatment with CTLA-41g. Clin. Invest. (1995) 9 6 :987–993.
   Google Scholar
• KHOURY SJ, AKALIN E, CHANDRAKER A, et al: CD28-B7costimulatory blockade by CTLA-4IgG prevents actively induced experimental autoimmune encepha-lomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. j immunoi. (1995) 155:4521–4524.
   PubMed Web of Science ®Google Scholar
• QUATTROCCHI E, DALLMAN MJ, FELDMAN M: Adenovirus-mediated gene transfer of CTLA-41g fusion protein in the suppression of experimental autoim-mune arthritis. Arthritis Rheum. (2000) 43:1688–1697.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL M, PLATTNER S: The treatment of rheuma-toid arthritis with OM-8980. J. Rheumatol. (1981) 40:228–231.
   Google Scholar
• BRACKERTZ D, VISCHER TL: OM-8980 in rheumatoid arthritis: a six month, double blind placebo controlled study. J. Rheumatol. (1989) 16:19–23.
   PubMed Web of Science ®Google Scholar
• VERSTRAENTEN A, SILEGHEM A, DEQUEKER J: OM-8980 and d-penicillamine in the treatment of rheumatoid arthritis: a 12 months double randomised blind study. Scand. j Rheumatol. (1990) 1 9 :422–431.
   Google Scholar
• HAUZEUR JP, APPLEBOM T: Double-blind placebo controlled study of OM-8980 in RA. Rheumatol. Int. (1989) 9:71–76.
   PubMed Web of Science ®Google Scholar
• VISCHER T: A double blind multicentre study of OM-8980 and auranoffin in RA. Ann. Rheum. Dis. (1988) 47:582–587.
   PubMed Web of Science ®Google Scholar
• STAINES NA, HARPER N, BEVAN DJ, THOMPSON HSG:Oral tolerance: potential therapy for autoimmune diseases. 8ème Symposium International dimmunorheu-matologie. Montpellier, France (1992):239–250.
   Google Scholar
• THOMAS TC, ROLLINS SA, ROTHER RP, et al.: Inhibition ofcomplement activity by humatised anti-05 antibody and single chain FC. Mol. Immunol. (1996) 33:1389–1401.
   PubMed Web of Science ®Google Scholar
• FEARON DT: Regulation of the amplification of C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Nati Acad. Sci. USA (1979) 76:5867–5871.
   PubMed Web of Science ®Google Scholar
• IIDA IC, NUSSENZWEIG V: Complement receptor is an inhibitor of complement cascade. J. Exp. Med. (1981) 153:1138–1150.
   PubMed Web of Science ®Google Scholar
• DREJA H, ANNENKOV A, CHERNAJOVSKY Y: Soluble complement receptor 1 (CD35) delivery by retrovi-r ally infected syngeneic cells or by naked DNA injection prevents progression of collagen induced arthritis. Arthritis Rheum. (2000) 43:1698–1709.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RO, MASON LM, FELDMANN, MAINI R: Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen induced arthritis. Proc. Natl. Acad. Sci. USA (1994) 91 :2762–2766.
   PubMed Web of Science ®Google Scholar
• JOOSTEN LAB, HELSEN MMA, VAN DE LOO FAJ, VAN DE BERG WB: Anticytokine treatment of established Type 2 collagen induced arthritis in DBA/1 mice; a compara-tive study using anti-TNF-a, anti-IL-113/a and IL-1Ra. Arthritis Rheum. (1996) 39:797–809.
   PubMed Web of Science ®Google Scholar
• GERLAG DM, BORGES E, ELLERBY HM, et al.: Targeted apoptosis of synovial neovasculature in murine collagen arthritis. Arthritis Rheum. (1999) 42:S120.
   Google Scholar